BiotechTube

Lonapegsomatropin

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adult Growth Hormone Deficiency

Conditions

Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency

Trial Timeline

Dec 16, 2021 → Dec 23, 2024

NCT ID
NCT05171855

About Lonapegsomatropin

Lonapegsomatropin is a phase 3 stage product being developed by Ascendis Pharma for Adult Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT05171855. Target conditions include Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05171855Phase 3Completed

Competing Products

20 competing products in Adult Growth Hormone Deficiency

See all competitors
ProductCompanyStageHype Score
BBP-398 + sotorasibBridgeBio PharmaPhase 1
30
Daridorexant + PlaceboIdorsiaPhase 1
28
SON-1010 (IL12-FHAB)Sonnet BioTherapeuticsPhase 1
28
SomatropinEli LillyPhase 3
77
agenT-797MiNK TherapeuticsPhase 1
25
PegilodecakinEli LillyPhase 1
33
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + TrastuzumabeFFECTOR TherapeuticsPhase 1/2
33
Lazertinib(G001) + Lazertinib(G002)YuhanPhase 1
33
Patritumab deruxtecanDaiichi SankyoPhase 2
52
DJ-927 + capecitabineDaiichi SankyoPhase 1
33
Valemetostat TosylateDaiichi SankyoPhase 2
52
RoxadustatAstellas PharmaPhase 1
33
ASP3325 + PlaceboAstellas PharmaPhase 1
33
TRK-100STPAstellas PharmaPhase 1
33
EnsitrelvirShionogiPhase 1
33
E6130 + PlaceboEisaiPhase 1
33
E7389 + E7389 + E7389EisaiPhase 1
33
Eribulin MesylateEisaiPhase 1
33
E2022 + E2022 + E2022 + E2022 + E2022EisaiPhase 1
33
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil HydrochlorideEisaiPhase 1
33

Other Products from Ascendis Pharma

Lonapegsomatropin + SomatropinPhase 3
74
Once weekly subcutaneous injection of TransCon hGH + Once daily subcutaneous injection of GenotropinPhase 3
74
TransCon hGHPhase 3
74
TransCon hGHPhase 3
74
TransCon hGH + daily hGHPhase 3
74